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The advent of liver transplantation provided a treatment
option for several pediatric terminal liver diseases. In
September 1989, we performed the first pediatric liver
transplantation in a child with biliary atresia at the Instituto
da Crianc¸a do Hospital das Clínicas da Faculdade de
Medicina da Universidade de São Paulo after an extensive
program of basic science and animal training. Thanks to
institutional efforts and the dedication of a multi-disciplinary
team composed of doctors, nurses, hospital administrators,
pharmacists, physiotherapists, nutritionists, social workers
and psychologists, it was possible for us to create and
maintain a Brazilian pediatric liver transplantation program
that is comparable to those of the world’s best centers. From
1989 to the present, we have performed 680 liver transplan-
tations in children with different terminal liver diseases,
including the most severe cases of fulminant hepatic failure.
However, the scarcity of suitable deceased donors has
been a great problem for all liver transplantation programs,
particularly in the pediatric area because the need to reduce
the volume of liver grafts and the relative severity of the
clinical conditions of our patients make the procurement of
deceased donors even more difficult and selective. The
positions of liver recipient candidates on the waiting list
(a single list for adults and children) were based on
chronologic criteria until June of 2006 and the mean time
from inclusion on the list until transplantation was three
years. Consequently, waiting-list mortality (affecting more
than 50% of patients) was an important problem that had
yet to be solved. From that time until the present, despite
the introduction of the Pediatric End-stage Liver Disease
(PELD)/Model for End-stage Liver Disease (MELD) criteria
for the inclusion and classification of patients based on the
severity of their hepatic disease and clinical conditions, the
waiting-list mortality rate has remained persistently high.
In this context, we began a program of living donor
transplantation and the first procedure was performed in
1998. To date, careful selection and preparation of potential
living donors have allowed us to perform 280 procedures,
with a low morbidity rate and no donor complications or
deaths (1). Resection of the left lateral segment or the left lobe
(which provides sufficient liver mass for pediatric recipients)
is a procedure that is relatively safe for the donors (2). Our
center’s surgical team includes only pediatric surgeons, with
extensive experience in pediatric liver surgery and liver
transplantation, including experience with adolescents, which
allows us to perform the donor hepatectomies without the
participation of adult surgeons. We emphasize that the donor
and recipient procedures are performed in adjoining rooms,
with full synchronization, in an exclusively pediatric hospital
that has undergone logistical and structural adjustments to
allow for the procedures in the adults to be performed safely
and comfortably. Additionally, in the early postoperative
period, the donor (in general, a mother or father) and the
recipient can stay together in the same hospital. Finally,
another advantage is that the team of pediatric surgeons can
perform adequate early and late follow-ups of all donors.
Regarding the benefits of living donor transplantation for
the recipients, the advantages of good-quality grafts out-
weigh the technical difficulties related to the smaller caliber
of the vascular anastomoses and to biliary reconstruction (3).
Thus, despite the introduction of MELD and PELD scores
to determine waiting-list positions, living donor liver trans-
plantation maintains a crucial role in our program because
children can be treated earlier and receive extensively
evaluated grafts with optimal function that have been
exposed to minimal cold ischemia.
However, liver transplantation is a complex procedure,
and as such, it is still associated with several postopera-
tive complications. Surgical complications may involve the
vascular (hepatic artery, portal vein and hepatic vein) and
biliary structures. In this context, we introduced the utiliza-
tion of simplified arterial microsuture techniques, which
make the performance of arterial anastomoses much easier
and more practical (4) and the precise utilization of arterial
grafts (5), which allows for progressively better results in
terms of arterial complications. Moreover, the utilization of a
Rex shunt (i.e., a bypass between the superior mesenteric vein
and the portal vein left branch) in cases of portal thrombosis
(6) and technical modification of the hepatic vein anastomosis
procedure, which involves the creation of a wide opening in
the anterior wall of the inferior vena cava (7), have been
responsible for a decrease in the rate of venous complications.
However, biliary complications and size mismatches remain
unsolved problems and are thus the subjects of important
experimental studies. A weaning rat model of selective biliary
obstruction was developed in our laboratory, with the aim
of improving our understanding of biliary cirrhosis in cases of
intrahepatic segmental biliary stenosis (8,9).DOI: 10.6061/clinics/2016(04)01
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Moreover, the consequences of engrafting liver grafts that
are disproportionately large relative to the recipients’ size,
i.e., cases of infant recipients who are less than 5 kg in size,
have not been completely elucidated. Therefore, we created
a new swine ‘‘large-for-size’’ liver transplantation model (10)
and many studies that have tentatively clarified the mole-
cular and flowmetric mechanisms of lesions in this situation
(11) as well as therapeutic measures to attenuate such lesions
have been reported (11).
Finally, the immunologic mechanisms involved in the
humoral and cellular rejection of solid organ transplants
remain a matter of continuing research in the literature.
Despite all of the advances in immunosuppressive regimens
and the development of accurate drugs with fewer collateral
effects, acute and chronic rejections remain dreaded compli-
cations of pediatric liver transplantation. The diagnoses of
acute and chronic rejection are based on histopathological
findings, and portal inflammation and centrilobular necrosis
are characteristics of acute rejection. Moreover, biliary duct
paucity in the portal space and foam cell arteriopathy are the
main aspects of chronic rejection (12). Regarding acute
cellular rejection, treatment and management are relatively
standardized and most cases exhibit good responses to
corticosteroid bolus treatments as well as tacrolimus level
adjustment (13). The treatment and evolution of pediatric
patients with chronic rejection are not well characterized, as
few published studies are present in the literature.
Indeed, the mechanisms of chronic rejection are not
completely known and the progressive biliary duct paucity
may not respond to increased immunosuppression, which
can lead to severe liver dysfunction, a need for retransplan-
tation or death, as discussed in the paper by Tannuri et al. in
the current issue of Clinics. Finally, the early histological
findings and histological aspects that are suggestive of
irreversibility must be defined, and prognostic factors after
chronic rejection is diagnosed must be identified, although
certain investigations have previously tried to identify the
risk factors for the development of chronic rejection follow-
ing liver transplantation in pediatric (14) and adult (15,16)
populations.
In conclusion, liver transplantation is a relatively
new procedure that allows for the survival of many
infants and children who otherwise would die. However,
this procedure also results in a number of conditions
and complications that have never been previously
recognized and treated. Therefore, much remains to be
studied and accomplished, particularly in the field of
immunology.
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